BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina...
BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina...
Ocular Therapeutix (NASDAQ:OCUL) Beats Expectations in Strong Q2 CY2026
Ocular Therapeutix: Q2 Earnings Snapshot
Ocular’s AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory...
3 Healthcare Stocks with Questionable Fundamentals
3 Russell 2000 Stocks That Concern Us
Pharmaceuticals Stocks Q1 In Review: Ocular Therapeutix (NASDAQ:OCUL) Vs Peers
3 Cash-Burning Stocks with Open Questions
BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina...